Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Hormone Resistant Prostate Cancer


Published on

A slide presentation on Hormone resistant prostate cancer and its management

Published in: Health & Medicine, Business

Hormone Resistant Prostate Cancer

  1. 1. Chemotherapy in HRPC Department of Medical oncology
  2. 2. Definition <ul><li>Hormone resistant prostate cancer </li></ul><ul><ul><li>A rising PSA despite androgen ablation </li></ul></ul><ul><ul><li>Manifests </li></ul></ul><ul><ul><ul><li>Rising PSA </li></ul></ul></ul><ul><ul><ul><li>Symotomatic Progression </li></ul></ul></ul><ul><ul><ul><li>Radiological evidence of progression despite the serum testosterone been at castrate levels </li></ul></ul></ul><ul><ul><li>BUT </li></ul></ul>
  3. 3. Defn contd <ul><li>Trials defined (similar) </li></ul><ul><ul><li>Men with advanced and progressive prostate cancer that had failed to respond to standard hormone therapy. Disease progression is observed despite castrate level of testosterone </li></ul></ul><ul><ul><li>The definition of disease progression </li></ul></ul><ul><ul><ul><li>appearance of new lesions </li></ul></ul></ul><ul><ul><ul><li>an increase in size (generally 25%) of existing lesions </li></ul></ul></ul><ul><ul><ul><li>an increase in pain </li></ul></ul></ul><ul><ul><ul><li>reduction in performance status </li></ul></ul></ul><ul><ul><ul><li>Decrease in weight </li></ul></ul></ul><ul><ul><ul><li>an increase in PSA levels </li></ul></ul></ul><ul><ul><li>No trial used a rising PSA level as the sole indicator of disease progression. </li></ul></ul>
  4. 4. EAU- defn <ul><li>Castrate serum levels of testosterone (testosterone <50 ng/dl or <1.7 nmol/l) </li></ul><ul><li> Three consecutive rises of PSA, 1 wk apart, resulting in two 50% increases over the nadir </li></ul><ul><li> Antiandrogen withdrawal for at least 4 wk for flutamide and for at least 6 wk for bicalutamide </li></ul><ul><li> PSA progression, despite consecutive hormonal manipulations </li></ul><ul><li> Progression of osseous lesions: progression or appearance of two or more lesions on bone scan or soft tissue lesions using Response Evaluation Criteria in Solid Tumours and with nodes >2 cm in diameter </li></ul>
  5. 5. Why treat? <ul><li>Morbidity </li></ul><ul><ul><li>QOL </li></ul></ul><ul><li>Mortality </li></ul><ul><ul><li>Incurable situation </li></ul></ul><ul><ul><li>Median life expectancy 12-18 months </li></ul></ul>Use of chemo for palliation Of symptoms and for survival benefit
  6. 6. Mitoxantrone The major toxicities were associated with mi- toxantrone include grade 3/4 neutropenia (7%), nausea and vomiting, alopecia (24%) and cardiotoxicity (66%).
  7. 7. Docetaxol TAX 327
  8. 8. Side effects
  9. 9. Other studies
  10. 10. Lesson learned? <ul><li>In view of the apparent lack of superior activity and greater toxicity by the addition of estramustine, docetaxel every 3 weeks plus low-dose prednisone can be considered as the current standard treatment </li></ul><ul><li>The optimal duration of docetaxel based chemotherapy for CRPC has not yet been established. </li></ul><ul><ul><li>Tax 327 10 cycles </li></ul></ul><ul><ul><li>SWOG 99-16 12 cycles. </li></ul></ul><ul><li>Standard practice is to treat patients with a fixed number of 10cycles of chemotherapy </li></ul>
  11. 11. Prognostic factors <ul><li>TAX 327 four independent risk factors predicted for not reaching a 30% PSA decline in 3-month PSA </li></ul><ul><ul><li>Significant baseline pain </li></ul></ul><ul><ul><li>Visceral metastases </li></ul></ul><ul><ul><li>anaemia (haemoglobin <13g/dl) </li></ul></ul><ul><ul><li>bone scan progression at baseline </li></ul></ul><ul><li>low-risk group 0−1 risk factors – Median OS 25.7 m </li></ul><ul><li>intermediate-risk group 2 risk factors – 18.7 m </li></ul><ul><li>high-risk group of patients 3−4 risk factors-12.8 months, </li></ul>
  12. 12. When to start therapy?
  13. 13. PSA DT
  14. 14. Response measurement <ul><li>PCWG 2 defined criteria of progression on the basis of changes in PSA, bone metastases, and measurable disease </li></ul><ul><ul><li>PSA progression has been defined as a 25% or greater increase and an absolute increase of 2ng/mL or more from the lowest documented PSA level,which is confirmed by a second value obtained 3 or more weeks later. </li></ul></ul><ul><ul><li>When the bone scan is the sole indicatorof progression- when at least two or more new lesions are seen on a bone scan compared with prior scans. </li></ul></ul><ul><ul><li>Measurable ds- RECIST </li></ul></ul><ul><li>Surrogate markers- 30% decline in PSA at 3 months and Post treatment PSA velocity </li></ul>
  15. 15. Addition in first line <ul><li>Endothelin receptor blockers </li></ul><ul><li>VEGF blockers </li></ul><ul><li>Calcitrol </li></ul><ul><li>Bisphosphonates </li></ul><ul><li>Vaccine immunotherapy </li></ul>
  16. 16. Endothelin recepetor <ul><li>Endothelin A – Atrasentan </li></ul><ul><ul><li>Phase 3 trial failed </li></ul></ul><ul><li>ZD4054 </li></ul>
  17. 18. <ul><li>VEGF </li></ul><ul><ul><li>CALGB 90401-Despite improvement in PFS, measurable disease response and post-therapy PSA decline, the addition of bevacizumab to docetaxel and prednisone did not improve OS in men with mCRPC, and was associated with greater morbidity and mortality </li></ul></ul><ul><ul><li>Afigerecpt (vegf trap) </li></ul></ul><ul><li>Calitriol </li></ul>
  18. 19. <ul><li>BUT </li></ul><ul><ul><li>Phase 3 trial was close by data safety monitoring commitee- high number of deaths </li></ul></ul>
  19. 20. <ul><li>Bisphosphonates </li></ul><ul><ul><li>Zolendronic </li></ul></ul><ul><ul><li>Riseadronate </li></ul></ul><ul><li>Vaccine immunotherapy </li></ul><ul><ul><li>Phase 3 trail was closed </li></ul></ul>Monotherapy of docetaxol remains std in first line
  20. 21. Denosumab <ul><li>Bone metastases from hormone-refractory (castration-resistant) prostate cancer (CRPC) are associated with RANKL-mediated osteoclast activation resulting in bone destruction and skeletal-related events (SRE) </li></ul><ul><li>Denosumab is a fully human monoclonal antibody against RANKL </li></ul><ul><li>120 mg subcut 4 weekly with ca and vit d supp </li></ul><ul><li>Denosumab demonstrated superiority over ZA in delaying or preventing SREs in patients with bone metastases from CRPC. </li></ul><ul><li>Adverse events were consistent in both treatment groups with those previously reported in advanced cancer populations. </li></ul>
  21. 22. Second line therapy <ul><li>Issues </li></ul><ul><ul><li>Elderly </li></ul></ul><ul><ul><li>Frail </li></ul></ul><ul><ul><li>Tolerability </li></ul></ul>
  22. 28. Metronomic chemotherapy <ul><li>HRPC who failed at least docetaxel-based chemotherapy were proposed metronomic cyclophosphamide-prednisolone regimen, and were prospectively registered </li></ul><ul><li>Metronomic cyclophosphamide prednisolone was safe, well tolerated, and demonstrated interesting clinical activity, yielding a </li></ul><ul><ul><li>prostate specific antigen decrease by ≥50% in 26% of patients </li></ul></ul><ul><ul><li>decrease by ≥30% in 48% of patients, but also favorable palliative effects on pain in 43% of patients. </li></ul></ul><ul><ul><li>The median progression-free survival was 6 months (95% CI: 4-8 months) and the median overall survival was 11 months (95% CI: 7-19 months). </li></ul></ul>
  23. 30. Conclusion <ul><li>Use of chemotherapy has increased survival in HRPC </li></ul><ul><li>The quest for newer and better agents in first and second line is ongiong </li></ul><ul><li>Use of metronomic in second line needs futher studies </li></ul>